[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-treatment-induced-thrombocytopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-treatment-induced-thrombocytopenia":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100626906","phase-2-safety-and-efficacy-of-umbilical-cord-blood-therapy-for-cancer-therapy-induced-thrombocytopenia-ctit-100626906",false,"NCT07441720","Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)","Inclusion Criteria:\n\n1. Aged 12 to 65 years at the time of signing the informed consent, regardless of gender.\n2. Meets the diagnostic criteria for cancer treatment-induced thrombocytopenia (CTIT):Peripheral blood platelet count \\\u003C 100 × 10⁹\u002FL; Prior definite exposure to a chemotherapy agent (or tumor-targeted therapy, immunotherapy, or other anti-tumor drugs) known to cause thrombocytopenia, with gradual improvement of thrombocytopenia-related symptoms\u002Fsigns or normalization of platelet count after discontinuation of the offending drug; Presence or absence of bleeding tendency, such as petechiae, purpura, unexplained epistaxis, or even severe organ\u002Ftissue hemorrhage;\n3. No significant hepatic or renal impairment: ALT and AST ≤ 2.5 × upper limit of normal (ULN), serum creatinine (Cr) and blood urea nitrogen (BUN) ≤ 1.25 × ULN;\n4. Karnofsky Performance Status (KPS) score ≥ 60 (see Appendix 1), Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix 2);\n5. Estimated life expectancy of more than 3 months.\n\nExclusion Criteria:\n\n1. Other causes of thrombocytopenia, in particular exclusion of underlying diseases or comorbidities such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenia (ITP), hypersplenism, or bone marrow infiltration by tumor cells;\n2. Use of non-anti-tumor medications known to cause thrombocytopenia (including but not limited to sulfonamides and other drugs);\n3. Pseudothrombocytopenia induced by ethylenediaminetetraacetic acid (EDTA) anticoagulant;\n4. Uncontrolled malignant tumor, hypertension, or diabetes mellitus;\n5. Active infection, including but not limited to known HIV positivity, active hepatitis B or C, or syphilis;\n6. Poor compliance;\n7. Known allergy or hypersensitivity to any component of the study intervention (umbilical cord blood or related products);\n8. Participation in another clinical trial within 1 month prior to enrollment or current participation in another clinical trial;\n9. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this clinical study.","ALL","12 Years","65 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients. It plans to recruit subjects aged 12 to 65 years old with CTIT. The study involves intravenous infusion of umbilical cord blood, with platelet transfusion as supportive therapy if necessary. The trial consists of three phases: screening (baseline assessments and enrollment), treatment (umbilical cord blood infusion), and follow-up (blood routine tests at Days 3, 7, 14, and 28 post-treatment to record platelet counts, first response time, maximum and minimum values, and calculate efficacy rates while observing changes in thrombocytopenia grading). A total of 25 subjects will be enrolled, and they will undergo evaluation for safety and efficacy based on treatment-related adverse events, GVHD incidence, and hematological improvements.",[26,27],"Thrombocytopenia","Cancer Treatment-induced Thrombocytopenia",[29,30,31],"Umbilical cord blood","Cancer treatment-induced thrombocytopenia","CTIT","RECRUITING","2026-05-05",{"date":35,"type":36},"2026-05-11","ACTUAL",{"date":38,"type":36},"2026-02-28",{"date":40,"type":20},"2027-12-30",{"name":42,"class":43},"Zhejiang Cancer Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100551164","phase-2-ql0911-for-the-treatment-of-cancer-treatment-induced-thrombocytopenia-100551164","NCT06456528","QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia","Phase 2\u002F3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.","Inclusion Criteria:\n\n* Men and women, 18-75 years of age;\n* Histopathological or cytological examination confirmed cancer , chemotherapy cycle of 21 days;\n* Participant experienced thrombocytopenia and chemotherapy delay;\n* ECOG performance status 0-1;\n* The estimated survival time at screening is ≥12 weeks, and the current chemotherapy regimen can be accepted for at least 2 cycles.\n\nExclusion Criteria:\n\n* Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia;\n* Participant has serious bleeding symptoms;\n* History of allergy to the study drug;\n* Patients with hepatitis C antibody positive and detection of HCV-RNA exceeding the upper limit, patients with hepatitis B surface antigen positive and detection of HBV-DNA exceeding the upper limit, patients with severe cirrhosis, HIV antibody positive and syphilis antibody positive;\n* Pregnant or lactating women;\n* Participant has received any experimental therapy within 28 days prior to screening\n* Other conditions that may affect participant's safety or trial evaluations per investigator's discretion","18 Years","75 Years",{"count":55,"type":20},235,[23,57],"PHASE3","To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.",[60],"Cancer Treatment-Induced Thrombocytopenia","2026-01-08",{"date":63,"type":36},"2026-01-12",{"date":65,"type":36},"2024-10-22",{"date":67,"type":20},"2026-12",{"name":69,"class":70},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY","Cancer Treatment Induced Thrombocytopenia"]